Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

Comparison of the Accuracy of FMT/CT and PET/MRI for the Assessment of Antibody Biodistribution in Squamous Cell Carcinoma Xenografts.

Hage C, Gremse F, Griessinger CM, Maurer A, Hoffmann SHL, Osl F, Pichler BJ, Kiessling F, Scheuer W, Pöschinger T.

J Nucl Med. 2018 Jan;59(1):44-50. doi: 10.2967/jnumed.117.197178. Epub 2017 Aug 28.

2.

Noninvasive Bioluminescence Imaging of AKT Kinase Activity in Subcutaneous and Orthotopic NSCLC Xenografts: Correlation of AKT Activity with Tumor Growth Kinetics.

Suchowski K, Pöschinger T, Rehemtulla A, Stürzl M, Scheuer W.

Neoplasia. 2017 Apr;19(4):310-320. doi: 10.1016/j.neo.2017.02.005. Epub 2017 Mar 9.

3.

Quantification of antiangiogenic treatment effects on tissue heterogeneity in glioma tumour xenograft model using a combination of DCE-MRI and 3D-ultramicroscopy.

Dominietto M, Dobosz M, Bürgi S, Renner A, Zahlmann G, Scheuer W, Rudin M.

Eur Radiol. 2017 Jul;27(7):2894-2902. doi: 10.1007/s00330-016-4629-3. Epub 2016 Nov 9.

PMID:
27830379
5.

TetraMabs: simultaneous targeting of four oncogenic receptor tyrosine kinases for tumor growth inhibition in heterogeneous tumor cell populations.

Castoldi R, Schanzer J, Panke C, Jucknischke U, Neubert NJ, Croasdale R, Scheuer W, Auer J, Klein C, Niederfellner G, Kobold S, Sustmann C.

Protein Eng Des Sel. 2016 Oct;29(10):467-475. doi: 10.1093/protein/gzw037. Epub 2016 Aug 29.

6.

RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis.

Brünker P, Wartha K, Friess T, Grau-Richards S, Waldhauer I, Koller CF, Weiser B, Majety M, Runza V, Niu H, Packman K, Feng N, Daouti S, Hosse RJ, Mössner E, Weber TG, Herting F, Scheuer W, Sade H, Shao C, Liu B, Wang P, Xu G, Vega-Harring S, Klein C, Bosslet K, Umaña P.

Mol Cancer Ther. 2016 May;15(5):946-57. doi: 10.1158/1535-7163.MCT-15-0647. Epub 2016 Apr 1.

7.

Anti-tumoral, anti-angiogenic and anti-metastatic efficacy of a tetravalent bispecific antibody (TAvi6) targeting VEGF-A and angiopoietin-2.

Scheuer W, Thomas M, Hanke P, Sam J, Osl F, Weininger D, Baehner M, Seeber S, Kettenberger H, Schanzer J, Brinkmann U, Weidner KM, Regula J, Klein C.

MAbs. 2016;8(3):562-73. doi: 10.1080/19420862.2016.1147640.

8.

Interferon Gamma Counteracts the Angiogenic Switch and Induces Vascular Permeability in Dextran Sulfate Sodium Colitis in Mice.

Haep L, Britzen-Laurent N, Weber TG, Naschberger E, Schaefer A, Kremmer E, Foersch S, Vieth M, Scheuer W, Wirtz S, Waldner M, Stürzl M.

Inflamm Bowel Dis. 2015 Oct;21(10):2360-71. doi: 10.1097/MIB.0000000000000490.

PMID:
26164664
9.

A novel glycoengineered bispecific antibody format for targeted inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor type I (IGF-1R) demonstrating unique molecular properties.

Schanzer JM, Wartha K, Croasdale R, Moser S, Künkele KP, Ries C, Scheuer W, Duerr H, Pompiati S, Pollman J, Stracke J, Lau W, Ries S, Brinkmann U, Klein C, Umana P.

J Biol Chem. 2014 Jul 4;289(27):18693-706. doi: 10.1074/jbc.M113.528109. Epub 2014 May 19.

10.

Dynamic contrast-enhanced micro-computed tomography correlates with 3-dimensional fluorescence ultramicroscopy in antiangiogenic therapy of breast cancer xenografts.

Pöschinger T, Renner A, Eisa F, Dobosz M, Strobel S, Weber TG, Brauweiler R, Kalender WA, Scheuer W.

Invest Radiol. 2014 Jul;49(7):445-56. doi: 10.1097/RLI.0000000000000038.

PMID:
24598441
12.

Apoptosis imaging for monitoring DR5 antibody accumulation and pharmacodynamics in brain tumors noninvasively.

Weber TG, Osl F, Renner A, Pöschinger T, Galbán S, Rehemtulla A, Scheuer W.

Cancer Res. 2014 Apr 1;74(7):1913-23. doi: 10.1158/0008-5472.CAN-13-3001. Epub 2014 Feb 7.

13.

Noninvasive measurement of pharmacokinetics by near-infrared fluorescence imaging in the eye of mice.

Dobosz M, Strobel S, Stubenrauch KG, Osl F, Scheuer W.

J Biomed Opt. 2014 Jan;19(1):16022. doi: 10.1117/1.JBO.19.1.016022.

14.

Ang-2-VEGF-A CrossMab, a novel bispecific human IgG1 antibody blocking VEGF-A and Ang-2 functions simultaneously, mediates potent antitumor, antiangiogenic, and antimetastatic efficacy.

Kienast Y, Klein C, Scheuer W, Raemsch R, Lorenzon E, Bernicke D, Herting F, Yu S, The HH, Martarello L, Gassner C, Stubenrauch KG, Munro K, Augustin HG, Thomas M.

Clin Cancer Res. 2013 Dec 15;19(24):6730-40. doi: 10.1158/1078-0432.CCR-13-0081. Epub 2013 Oct 4.

16.

A novel bispecific EGFR/Met antibody blocks tumor-promoting phenotypic effects induced by resistance to EGFR inhibition and has potent antitumor activity.

Castoldi R, Ecker V, Wiehle L, Majety M, Busl-Schuller R, Asmussen M, Nopora A, Jucknischke U, Osl F, Kobold S, Scheuer W, Venturi M, Klein C, Niederfellner G, Sustmann C.

Oncogene. 2013 Dec 12;32(50):5593-601. doi: 10.1038/onc.2013.245. Epub 2013 Jul 1.

17.

A novel angiopoietin-2 selective fully human antibody with potent anti-tumoral and anti-angiogenic efficacy and superior side effect profile compared to Pan-Angiopoietin-1/-2 inhibitors.

Thomas M, Kienast Y, Scheuer W, Bähner M, Kaluza K, Gassner C, Herting F, Brinkmann U, Seeber S, Kavlie A, Welschof M, Ries S, Weidner KM, Regula JT, Klein C.

PLoS One. 2013;8(2):e54923. doi: 10.1371/journal.pone.0054923. Epub 2013 Feb 6.

18.

Targeted siRNA Delivery and mRNA Knockdown Mediated by Bispecific Digoxigenin-binding Antibodies.

Schneider B, Grote M, John M, Haas A, Bramlage B, Ickenstein LM, Jahn-Hofmann K, Bauss F, Cheng W, Croasdale R, Daub K, Dill S, Hoffmann E, Lau W, Burtscher H, Ludtke JL, Metz S, Mundigl O, Neal ZC, Scheuer W, Stracke J, Herweijer H, Brinkmann U.

Mol Ther Nucleic Acids. 2012 Sep 18;1:e46. doi: 10.1038/mtna.2012.39.

19.

Drug-based optical agents: infiltrating clinics at lower risk.

Scheuer W, van Dam GM, Dobosz M, Schwaiger M, Ntziachristos V.

Sci Transl Med. 2012 May 16;4(134):134ps11. doi: 10.1126/scitranslmed.3003572. Review. Erratum in: Sci Transl Med. 2012 Jun 13;4(138):138er3.

PMID:
22593172
20.

Bioluminescence imaging correlates with tumor serum marker, organ weights, histology, and human DNA levels during treatment of orthotopic tumor xenografts with antibodies.

Poeschinger T, Renner A, Weber T, Scheuer W.

Mol Imaging Biol. 2013 Feb;15(1):28-39. doi: 10.1007/s11307-012-0559-x.

PMID:
22528864
21.

Development of tetravalent IgG1 dual targeting IGF-1R-EGFR antibodies with potent tumor inhibition.

Croasdale R, Wartha K, Schanzer JM, Kuenkele KP, Ries C, Mayer K, Gassner C, Wagner M, Dimoudis N, Herter S, Jaeger C, Ferrara C, Hoffmann E, Kling L, Lau W, Staack RF, Heinrich J, Scheuer W, Stracke J, Gerdes C, Brinkmann U, Umana P, Klein C.

Arch Biochem Biophys. 2012 Oct 15;526(2):206-18. doi: 10.1016/j.abb.2012.03.016. Epub 2012 Mar 21.

PMID:
22464987
22.

Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies.

Schaefer W, Regula JT, Bähner M, Schanzer J, Croasdale R, Dürr H, Gassner C, Georges G, Kettenberger H, Imhof-Jung S, Schwaiger M, Stubenrauch KG, Sustmann C, Thomas M, Scheuer W, Klein C.

Proc Natl Acad Sci U S A. 2011 Jul 5;108(27):11187-92. doi: 10.1073/pnas.1019002108. Epub 2011 Jun 20.

23.

Bispecific digoxigenin-binding antibodies for targeted payload delivery.

Metz S, Haas AK, Daub K, Croasdale R, Stracke J, Lau W, Georges G, Josel HP, Dziadek S, Hopfner KP, Lammens A, Scheuer W, Hoffmann E, Mundigl O, Brinkmann U.

Proc Natl Acad Sci U S A. 2011 May 17;108(20):8194-9. doi: 10.1073/pnas.1018565108. Epub 2011 May 2.

24.

Cancer-related issues of CD147.

Weidle UH, Scheuer W, Eggle D, Klostermann S, Stockinger H.

Cancer Genomics Proteomics. 2010 May-Jun;7(3):157-69. Review.

PMID:
20551248
25.

Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models.

Scheuer W, Friess T, Burtscher H, Bossenmaier B, Endl J, Hasmann M.

Cancer Res. 2009 Dec 15;69(24):9330-6. doi: 10.1158/0008-5472.CAN-08-4597.

26.
27.
28.

Activation of cytosolic phospholipase A2 in human T-lymphocytes involves inhibitor-kappaB and mitogen-activated protein kinases.

Burgermeister E, Endl J, Scheuer WV.

Eur J Pharmacol. 2003 Apr 11;466(1-2):169-80.

PMID:
12679154
29.

Comparative analysis of docking motifs in MAP-kinases and nuclear receptors.

Burgermeister E, Lanzendoerfer M, Scheuer W.

J Biomol Struct Dyn. 2003 Apr;20(5):623-34.

PMID:
12643765
30.
31.

Interleukin-16 stimulates the expression and production of pro-inflammatory cytokines by human monocytes.

Mathy NL, Scheuer W, Lanzendörfer M, Honold K, Ambrosius D, Norley S, Kurth R.

Immunology. 2000 May;100(1):63-9.

32.

Inhibition of cytosolic phospholipase A(2) attenuates activation of mitogen-activated protein kinases in human monocytic cells.

Burgermeister E, Pessara U, Tibes U, Küster A, Heinrich PC, Scheuer WV.

Eur J Pharmacol. 2000 Feb 4;388(3):195-208.

PMID:
10675727
33.

Suppression of acute experimental inflammation by antisense oligonucleotides targeting secretory phospholipase A2 (sPLA2) in vitro and in vivo experiments.

Tibes U, Röhr SP, Scheuer W, Amandi-Burgermeister E, Litters A.

Adv Exp Med Biol. 1999;469:199-207.

PMID:
10667331
34.

Phospholipase A2 is involved in chemotaxis of human leukocytes.

Tibes U, Hinder M, Scheuer W, Friebe WG, Schramm S, Kaiser B.

Adv Exp Med Biol. 1999;469:189-97. No abstract available.

PMID:
10667330
35.

Activation of nuclear factor-kappaB by lipopolysaccharide in mononuclear leukocytes is prevented by inhibitors of cytosolic phospholipase A2.

Burgermeister E, Tibes U, Stockinger H, Scheuer WV.

Eur J Pharmacol. 1999 Mar 26;369(3):373-86.

PMID:
10225377
36.

Suppression of cytokine synthesis, integrin expression and chronic inflammation by inhibitors of cytosolic phospholipase A2.

Amandi-Burgermeister E, Tibes U, Kaiser BM, Friebe WG, Scheuer WV.

Eur J Pharmacol. 1997 May 20;326(2-3):237-50.

PMID:
9196277
37.

(+)-10 alpha-Hydroxy-4-muurolen-3-one, a new inhibitor of leukotriene biosynthesis from a Favolaschia species. Comparison with other sesquiterpenes.

Zapf S, Wunder A, Anke T, Klostermeyer D, Steglich W, Shan R, Sterner O, Scheuer W.

Z Naturforsch C J Biosci. 1996 Jul-Aug;51(7-8):487-91.

PMID:
8810091
38.

Evidence for activation of cyclooxygenase-1/-2 by endogenous nitric oxide in adjuvant arthritic Lewis rats.

Thierse HJ, Friebe WG, Scheuer W, Voelter W, Tibes U.

Adv Exp Med Biol. 1996;416:343-8. No abstract available.

PMID:
9131171
39.

Inhibition of allergic and non-allergic inflammation by phospholipase A2 inhibitors.

Tibes U, Vondran A, Rodewald E, Friebe WG, Schäfer W, Scheuer W.

Int Arch Allergy Immunol. 1995 May-Jun;107(1-3):432-4. Review. No abstract available.

PMID:
7613203
40.
41.

Induction of cytosolic phospholipase A2 in human leukocytes by lipopolysaccharide.

Rodewald E, Tibes U, Maass G, Scheuer W.

Eur J Biochem. 1994 Aug 1;223(3):743-9.

42.

Oligomycin F, a new immunosuppressive homologue of oligomycin A.

Laatsch H, Kellner M, Wolf G, Lee YS, Hansske F, Konetschny-Rapp S, Pessara U, Scheuer W, Stockinger H.

J Antibiot (Tokyo). 1993 Sep;46(9):1334-41.

43.

Combinatorial functions of two chimeric antibodies directed to human CD4 and one directed to the alpha-chain of the human interleukin-2 receptor.

Weissenhorn W, Scheuer W, Kaluza B, Schwirzke M, Reiter C, Flieger D, Lenz H, Weiss EH, Rieber EP, Riethmüller G, et al.

Gene. 1992 Nov 16;121(2):271-8.

PMID:
1446824
44.

Complex Ca2+ flux inhibition as primary mechanism of staurosporine-induced impairment of T cell activation.

Kubbies M, Goller B, Russmann E, Stockinger H, Scheuer W.

Eur J Immunol. 1989 Aug;19(8):1393-8.

PMID:
2570702
45.

Phospholipase A2--regulation and inhibition.

Scheuer W.

Klin Wochenschr. 1989 Feb 1;67(3):153-9.

PMID:
2927053
46.

Modulation of the induction and circumvention of immunological tolerance to human gamma-globulin by interleukin 1.

Weigle WO, Scheuer WV, Hobbs MV, Morgan EL, Parks DE.

J Immunol. 1987 Apr 1;138(7):2069-74.

PMID:
2435789
48.

Interference with tolerance induction in vivo by inhibitors of prostaglandin synthesis.

Scheuer WV, Hobbs MV, Weigle WO.

Cell Immunol. 1987 Feb;104(2):409-18.

PMID:
2434247
49.

Antagonistic regulatory properties of the Fc region of immunoglobulin.

Morgan EL, Scheuer WV, Hobbs MV.

Immunopharmacology. 1986 Dec;12(3):221-32.

PMID:
3102401
50.

Binding of a synthetic analogue of mitogenic bacterial lipoprotein to murine major histocompatibility complex (MHC) gene products.

Scheuer WV, Biesert L, Bessler WG.

Biol Chem Hoppe Seyler. 1986 Oct;367(10):1085-94.

PMID:
3491614

Supplemental Content

Loading ...
Support Center